The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1575
ISSUE 1575
July 1, 2019
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
July 1, 2019 (Issue: 1575)
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Estradiol Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
Article code: 1575b
Electronic, downloadable article - $45
Article code: 1575b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
